Blair William & Co. IL Reduces Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Blair William & Co. IL lowered its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 85.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,800 shares of the biotechnology company’s stock after selling 27,542 shares during the quarter. Blair William & Co. IL’s holdings in BioMarin Pharmaceutical were worth $339,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Dodge & Cox boosted its holdings in BioMarin Pharmaceutical by 6.1% in the fourth quarter. Dodge & Cox now owns 14,746,235 shares of the biotechnology company’s stock worth $969,270,000 after purchasing an additional 847,917 shares during the last quarter. Capital Research Global Investors raised its position in BioMarin Pharmaceutical by 23.8% in the fourth quarter. Capital Research Global Investors now owns 12,991,772 shares of the biotechnology company’s stock worth $853,944,000 after acquiring an additional 2,496,817 shares during the period. Northern Trust Corp raised its position in BioMarin Pharmaceutical by 16.2% in the fourth quarter. Northern Trust Corp now owns 1,725,039 shares of the biotechnology company’s stock worth $113,387,000 after acquiring an additional 240,681 shares during the period. AQR Capital Management LLC raised its position in BioMarin Pharmaceutical by 114.5% in the fourth quarter. AQR Capital Management LLC now owns 1,283,599 shares of the biotechnology company’s stock worth $84,371,000 after acquiring an additional 685,099 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in BioMarin Pharmaceutical by 19.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,055,087 shares of the biotechnology company’s stock worth $69,351,000 after acquiring an additional 174,634 shares during the period. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Insider Transactions at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,786 shares of BioMarin Pharmaceutical stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $59.31, for a total value of $105,927.66. Following the sale, the chief accounting officer directly owned 14,173 shares in the company, valued at approximately $840,600.63. The trade was a 11.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on BMRN. Morgan Stanley decreased their price target on shares of BioMarin Pharmaceutical from $97.00 to $96.00 and set an “overweight” rating on the stock in a research report on Tuesday, July 22nd. JPMorgan Chase & Co. increased their price target on shares of BioMarin Pharmaceutical from $108.00 to $113.00 and gave the stock an “overweight” rating in a research report on Monday, July 14th. Wolfe Research set a $95.00 price target on shares of BioMarin Pharmaceutical and gave the stock an “outperform” rating in a research report on Tuesday, July 15th. UBS Group increased their price target on shares of BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Finally, Citigroup decreased their price target on shares of BioMarin Pharmaceutical from $82.00 to $78.00 and set a “neutral” rating on the stock in a research report on Friday, May 2nd. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, BioMarin Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $93.17.

BioMarin Pharmaceutical Stock Performance

Shares of NASDAQ BMRN opened at $56.80 on Tuesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.60 and a current ratio of 5.56. The company has a market cap of $10.91 billion, a P/E ratio of 16.85, a P/E/G ratio of 0.74 and a beta of 0.18. The firm’s fifty day moving average is $57.29 and its two-hundred day moving average is $61.70. BioMarin Pharmaceutical Inc. has a 52-week low of $52.93 and a 52-week high of $94.85.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.